English Journal

Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.

Gubbels JA, Gadbaw B, Buhtoiarov IN, Horibata S, Kapur AK, Patel D, Hank JA, Gillies SD, Sondel PM, Patankar MS, Connor J.SourceDepartment of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, WI 53711, USA. jennifer.gubbels@augie.edu
Cancer immunology, immunotherapy : CII.Cancer Immunol Immunother.2011 Dec;60(12):1789-800. doi: 10.1007/s00262-011-1072-9. Epub 2011 Jul 27.
The huKS-IL2 immunocytokine (IC) consists of IL2 fused to a mAb against EpCAM, while the hu14.18-IL2 IC recognizes the GD2 disialoganglioside. They are under evaluation for treatment of EpCAM(+) (ovarian) and GD2(+) (neuroblastoma and melanoma) malignancies because of their proven ability to enhance
PMID 21792658

Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.

Johnson EE, Yamane BH, Buhtoiarov IN, Lum HD, Rakhmilevich AL, Mahvi DM, Gillies SD, Sondel PM.SourceDepartments of Surgery, Human Oncology, and Pediatrics and Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI 53792, USA.
Clinical cancer research : an official journal of the American Association for Cancer Research.Clin Cancer Res.2009 Aug 1;15(15):4875-84. doi: 10.1158/1078-0432.CCR-09-0110. Epub 2009 Jul 28.
PURPOSE: Radiofrequency ablation (RFA) is a common treatment modality for surgically unresectable tumors. However, there is a high rate of both local and systemic recurrence.EXPERIMENTAL DESIGN: In this preclinical study, we sought to enhance the antitumor effect of RFA by combining it with huKS-IL2
PMID 19638464

Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer.

Ko YJ, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, Kovar A, Dahl T, Gillies SD.SourceBeth Israel Deaconess Medical Center, Boston, MA, USA.
Journal of immunotherapy (Hagerstown, Md. : 1997).J Immunother.2004 May-Jun;27(3):232-9.
This phase 1 clinical trial was conducted to evaluate the safety and to determine the maximum tolerated dose (MTD) of the immunocytokine EMD 273066 huKS-IL2 and, secondarily, to assess its pharmacokinetics, immunogenic potential, and immunologic activity in patients with androgen-independent prostat
PMID 15076141